Tags

Type your tag names separated by a space and hit enter

The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes.
Eur J Endocrinol. 2010 Jul; 163(1):45-54.EJ

Abstract

CONTEXT

The GH-2000 team proposed a method based on IGF1 and type III pro-collagen (P-III-P) to detect exogenously administered GH. As previous studies involved predominantly white European athletes, it is important to assess whether the response of these markers to recombinant human GH (rhGH) differs with ethnicity.

OBJECTIVE

To examine the response of serum IGF1 and P-III-P and GH-2000 score to rhGH in non-Caucasian amateur athletes.

DESIGN

Double-blind placebo-controlled rhGH administration study.

SETTING

Wellcome Trust Clinical Research Facility, Southampton General Hospital.

SUBJECTS

The study included 31 male and 14 female amateur athletes of different ethnicities. Intervention The subjects were assigned to treatment with placebo or 0.1 IU/kg per day (low dose) or 0.2 IU/kg per day (high dose) rhGH for 28 days. Blood was collected weekly during treatment and on days 35, 42 and 84 during the washout period. Serum IGF1 and P-III-P were measured, and GH-2000 score was calculated.

RESULTS

IGF1, P-III-P and GH-2000 score rose in response to both low- and high-dose GH in both men and women. When compared with the Caucasian volunteers of the previous GH-2000 study, mean baseline and placebo-treated P-III-P and GH-2000 score were lower in GH-2004 men and women. Post-GH, however, peak IGF1 or P-III-P did not differ between studies but the peak GH-2000 score was lower in GH-2004 men. There was no difference between studies in the maximal change in IGF1, P-III-P and GH-2000 score in response to GH in either gender.

CONCLUSIONS

These data do not support a significant ethnic effect on the peak or maximal response to rhGH.

Authors+Show Affiliations

Endocrinology and Metabolism, Developmental Origins of Health and Disease Division, The Institute of Developmental Sciences IDS Building, MP887, Southampton General Hospital, University of Southampton School of Medicine, Tremona Road, Southampton SO16 6YD, UK. .i.g.holt@southampton.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20421332

Citation

Holt, Richard I G., et al. "The GH-2004 Project: the Response of IGF1 and Type III Pro-collagen to the Administration of Exogenous GH in non-Caucasian Amateur Athletes." European Journal of Endocrinology, vol. 163, no. 1, 2010, pp. 45-54.
Holt RI, Erotokritou-Mulligan I, McHugh C, et al. The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes. Eur J Endocrinol. 2010;163(1):45-54.
Holt, R. I., Erotokritou-Mulligan, I., McHugh, C., Bassett, E. E., Bartlett, C., Fityan, A., Bacon, J. L., Cowan, D. A., & Sönksen, P. H. (2010). The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes. European Journal of Endocrinology, 163(1), 45-54. https://doi.org/10.1530/EJE-09-0978
Holt RI, et al. The GH-2004 Project: the Response of IGF1 and Type III Pro-collagen to the Administration of Exogenous GH in non-Caucasian Amateur Athletes. Eur J Endocrinol. 2010;163(1):45-54. PubMed PMID: 20421332.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes. AU - Holt,Richard I G, AU - Erotokritou-Mulligan,Ioulietta, AU - McHugh,Cathy, AU - Bassett,E Eryl, AU - Bartlett,Christiaan, AU - Fityan,Adam, AU - Bacon,Jenny L, AU - Cowan,David A, AU - Sönksen,Peter H, Y1 - 2010/04/26/ PY - 2010/4/28/entrez PY - 2010/4/28/pubmed PY - 2010/7/6/medline SP - 45 EP - 54 JF - European journal of endocrinology JO - Eur J Endocrinol VL - 163 IS - 1 N2 - CONTEXT: The GH-2000 team proposed a method based on IGF1 and type III pro-collagen (P-III-P) to detect exogenously administered GH. As previous studies involved predominantly white European athletes, it is important to assess whether the response of these markers to recombinant human GH (rhGH) differs with ethnicity. OBJECTIVE: To examine the response of serum IGF1 and P-III-P and GH-2000 score to rhGH in non-Caucasian amateur athletes. DESIGN: Double-blind placebo-controlled rhGH administration study. SETTING: Wellcome Trust Clinical Research Facility, Southampton General Hospital. SUBJECTS: The study included 31 male and 14 female amateur athletes of different ethnicities. Intervention The subjects were assigned to treatment with placebo or 0.1 IU/kg per day (low dose) or 0.2 IU/kg per day (high dose) rhGH for 28 days. Blood was collected weekly during treatment and on days 35, 42 and 84 during the washout period. Serum IGF1 and P-III-P were measured, and GH-2000 score was calculated. RESULTS: IGF1, P-III-P and GH-2000 score rose in response to both low- and high-dose GH in both men and women. When compared with the Caucasian volunteers of the previous GH-2000 study, mean baseline and placebo-treated P-III-P and GH-2000 score were lower in GH-2004 men and women. Post-GH, however, peak IGF1 or P-III-P did not differ between studies but the peak GH-2000 score was lower in GH-2004 men. There was no difference between studies in the maximal change in IGF1, P-III-P and GH-2000 score in response to GH in either gender. CONCLUSIONS: These data do not support a significant ethnic effect on the peak or maximal response to rhGH. SN - 1479-683X UR - https://www.unboundmedicine.com/medline/citation/20421332/The_GH_2004_project:_the_response_of_IGF1_and_type_III_pro_collagen_to_the_administration_of_exogenous_GH_in_non_Caucasian_amateur_athletes_ L2 - https://eje.bioscientifica.com/doi/10.1530/EJE-09-0978 DB - PRIME DP - Unbound Medicine ER -